StockData
BioNTech SE logo

BioNTech SE (BNTX) stock

BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 10, 2026Score 3/30
$83.26−1.60 (-1.89%)

Close on Nov 18, 2026Market cap $20.92BP/E –Yield –

BioNTech operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -€1.40B. The highest annual figure on record is €15.28B in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€1.40B–
FY2024Dec 31, 2024-€1.31B-290.4%
FY2023Dec 31, 2023€690.40M-94.5%
FY2022Dec 31, 2022€12.64B-17.3%
FY2021Dec 31, 2021€15.28B–
FY2020Dec 31, 2020-€82.40M–
FY2019Dec 31, 2019-€181.50M–
FY2018Dec 31, 2018-€53.85M–
FY2017Dec 31, 2017-€61.28M–

More BioNTech figures

See a number that looks wrong?